Hoibian Solène, Ratone Jean-Philippe, Gonzalez Jean-Michel, Bories Erwan, Pesenti Christian, Caillol Fabrice, Grimaud Jean-Charles, Giovannini Marc, Barthet Marc
Gastroenterology Unit, Hôpitaux Universitaires de Marseille Nord, Chemin des Bourrely (Solène Hoibian, Jean-Michel Gonzalez, Jean-Charles Grimaud, Marc Barthet).
Endoscopy Unit, Paoli-Calmettes Institute (Solène Hoibian, Jean-Philippe Ratone, Jean-Michel Gonzaleza Erwan Bories, Christian Pesenti, Fabrice Caillol, Marc Giovannini), Marseille, France.
Ann Gastroenterol. 2021;34(2):169-176. doi: 10.20524/aog.2021.0581. Epub 2021 Jan 27.
The long-term outcomes and safety of endoscopic mucosal resection (EMR) of sporadic duodenal adenoma (SDA), and the management of adverse events need to be confirmed.
A bicentric retrospective study was performed including all patients who underwent EMR for SDAs from 2003-2016. The primary aim was to evaluate the efficiency of EMR for SDA. The secondary objectives were to assess safety, recurrence management, predictive factors for treatment success, and adverse events.
One hundred thirty patients (134 procedures) were included (median age 65 years, 49.3% male). The mean SDA size was 20.7 (range 5-50) mm. Of the SDAs, 58.2% were category 3 of the Vienna classification, 35.8% were category 4, and 5.9% were category 5. The median follow up was 25.0 (range 2-120) months. Complete mucosal resection was achieved for 129/134 lesions (96.2%), with en bloc resection in 59/134 (44%). Recurrence occurred in 28.6% of cases (30/105 procedures). Recurrence was successfully treated by new endoscopic procedures in 72.2% (13/18) and by surgery in 27.8% (5/18). Delayed bleeding occurred in 13.4% of cases (18/134) and was successfully managed endoscopically. The perforation rate was 3.7% (5/134); perforations were managed without surgery in 60% (3/5 patients) of cases.
Endoscopic treatment of SDA appears to be effective and relatively safe in tertiary centers. All bleeding complications were endoscopically controlled, and perforation was rare. Recurrence was frequent but could be managed endoscopically. EMR is confirmed as a first-line treatment in cases of SDA, and surgery is useful only if repeated EMRs fail.
散发性十二指肠腺瘤(SDA)内镜黏膜切除术(EMR)的长期疗效和安全性,以及不良事件的处理仍需证实。
进行了一项双中心回顾性研究,纳入了2003年至2016年期间接受SDA的EMR治疗的所有患者。主要目的是评估EMR治疗SDA的有效性。次要目标是评估安全性、复发管理、治疗成功的预测因素和不良事件。
共纳入130例患者(134例手术)(中位年龄65岁,男性占49.3%)。SDA的平均大小为20.7(范围5-50)mm。在SDA中,58.2%为维也纳分类3类,35.8%为4类,5.9%为5类。中位随访时间为25.0(范围2-120)个月。134个病变中有129个(96.2%)实现了完整的黏膜切除,其中59个(44%)为整块切除。28.6%的病例(30/105例手术)出现复发。72.2%(13/18)的复发通过新的内镜手术成功治疗,27.8%(5/18)通过手术治疗。13.4%的病例(18/134)发生延迟出血,通过内镜成功处理。穿孔率为3.7%(5/134);60%(3/5例患者)的穿孔无需手术处理。
在三级中心,SDA的内镜治疗似乎有效且相对安全。所有出血并发症均通过内镜控制,穿孔罕见。复发常见,但可通过内镜处理。EMR被确认为SDA病例的一线治疗方法,仅在重复EMR失败时手术才有用。